Dexcom (DXCM) stock crashed late Thursday though the diabetes devices player beat Wall Street's third-quarter expectations and reiterated its outlook for the year.
↑ X NOW PLAYING How To Buy Stocks: Profit From Earnings Reports Using This Option Strategy
In the September quarter, Dexcom earned an adjusted 45 cents a share, beating expectations by two pennies. Earnings dipped 14% year over year. Sales edged 2% higher to $994.2 million, topping the Street view for $990 million, according to FactSet.
Organically, sales advanced 3% vs. the year-ago period.
Dexcom also reiterated its guidance for the year. The company calls for $4 billion to $4.05 billion in sales, vs. analysts' projection for $4.01 billion. That represents 11% to 13% organic sales growth.
In after-hours trades, Dexcom stock plunged more than 13% to 64.60.
More to follow.
Follow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.
YOU MAY ALSO LIKE:
Boston Scientific's Rockstar Segment Just Fumbled — And So Did Its Shares
Viking Therapeutics Skyrockets After Dealing A Blow To Eli Lilly's Obesity Triplet
Join IBD Live For Stock Ideas Each Morning Before The Open
Comments